CardioExcyte 96: High-Throughput, Non-Invasive Platform for Cardiac Electrophysiology and Toxicology

About This Grant

PROJECT SUMMARY/ABSTRACT The CardioExcyte 96 is an advanced, label-free, impedance-based electrophysiology system designed for high- throughput, real-time monitoring of cardiac cell activity. Utilizing 96-well plates, it enables the non-invasive measurement of key cardiac parameters such as action potentials, contractility, and heart rate variability without the need for electrodes or dyes. This technology provides a powerful, scalable solution for assessing cardiac function, making it highly suitable for studies involving drug-induced cardiotoxicity, cardiovascular diseases, and diverse cell models. A major limitation in current cardiac research is the lack of platforms that combine high- throughput capability with detailed, non-invasive electrophysiological analysis. This gap has slowed progress in critical areas like drug safety testing, disease modeling, and personalized medicine. The acquisition of the CardioExcyte 96 will directly address this need by providing our institution with cutting-edge technology to enhance both the quality and efficiency of cardiovascular research. Integrating this system into existing workflows will support a wide range of investigations in cardiac electrophysiology, offering researchers the ability to generate high-resolution, real-time data that can accelerate discovery. The primary objectives of this project are to improve the accuracy and throughput of cardiac screening in drug development, advance studies on arrhythmias and cardiotoxicity, and foster collaboration across multiple research domains. Overall, the CardioExcyte 96 will significantly strengthen our institution's research infrastructure, enabling scientists to tackle key challenges in cardiovascular biology and therapeutic innovation more effectively.